

5 November 2024

AMERICAN MEDICAL ASSOCIATION CONTINUES TO SUPPORT REMOTE PATIENT MONITORING, RECOMMENDING SIGNIFICANT POSITIVE CHANGES TO PATIENT REIMBURSEMENT CRITERIA.

Respiri Limited (ASX:RSH; OTCQB:RSHUF) ("Respiri") is an eHealth SaaS Company supporting Connected Care Management in the US the market. The American Medical Association (AMA) recently announced proposed changes to reimbursement criteria for Remote Patient Monitoring (RPM) programs that will significantly improve patient access and make criteria easier for Providers to claim these reimbursed services. These changes come into effect in January, 2026 and are a continued endorsement of these critical medical services that have significant positive impacts of the lives of patients and will continue to underpin the growth trajectory and opportunity for Respiri.

Proposed Changes

- **Revise the current requirement for CPT code 99454 from 16 days to 2 days** of collected and transmitted data in a 30-day rolling period.
- **Revise CPT code 99457 to include 11-20 minutes, down from at least 20 minutes.** This reduces the amount of time clinical staff must engage in interactive communication with a patient/caregiver during the month for 99457.
- **Revise CPT 99458 to cover each additional 10 minutes of interactive communication, down from an additional 20 minutes.** This reduces the amount of additional time clinical staff must engage in interactive communication for 99458.

These changes, expected to be endorsed by the Centers of Medicare and Medicaid Services (CMS) during 2025, will deliver immediate incremental revenue to Respiri's existing RPM program patients. The proposed changes to CPT code 99454, the collected and transmission of data, such as the wheeze-rate recordings delivered by FDA-cleared device wheezo®, could result in the number of Respiri-managed patients qualifying for monthly reimbursement to increase from **50%-70% to 90%** or an additional **US\$108K+** pa for every 1,000 patients on Respiri's RPM program. Further with changes to CPT codes 99457 and 99458, the clinical staff monitoring codes, Respiri projects a **100% increase** in monitoring services delivered by Respiri clinical staff which at current reimbursement fees may increase Respiri's per patient per month (pppm) fees from **US\$70-US\$90 to US\$140-US\$180**. New reimbursement rates are yet to be finalized and announced by CMS but regardless, RPM services appear to be part of the reimbursement landscape for the foreseeable future.

The AMAs proposed changes further validates Respiri's strategic approach in establishing a full suite of Connected Care Management programs, which reduce hospital re-admission rates and Emergency Department visits (ASX Announcement 4th October, 2024). These proposed changes demonstrate an ongoing commitment by the AMA to these important healthcare services as they provide significant benefits for patients, providers and payors by reducing clinical events, improving patient health outcomes and reduce unnecessary healthcare costs.



Respiri CEO, Marjan Mikel said “These changes reinforce the importance of the services Respiri helps provide to patients and is a recognition that they are an important piece of the healthcare investment mix. There appears to be an acceptance that negotiating the growing cost burden of healthcare provision will require a different approach and a different mix of services to deliver outcomes more cost effectively and that RPM is a critical part of this. We are very well positioned to continue to improve patient’s lives and be rewarded for doing so”.

Approved by the Board of Respiri Limited

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

About Respiri Limited – A Revolutionary Remote Healthcare Solutions Provider

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is leading the charge in transforming healthcare delivery in the US. As an innovator in medical devices and MedTech, we combine state-of-the-art technologies with unparalleled clinical expertise. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We're revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at www.respiri.co/au

About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Respiri, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiri™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respiri.co/us> or for [wheezo®](#)

Respiri Limited is headquartered in Melbourne with offices in New York City and Miami.

wheezo® is a registered trademark of Respiri Limited

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.